Muscle disorders associated with cyclosporine treatment

Muscle and Nerve

Volumn 22, Issue 12, 1999, Pages 1631-1636

  Breil, Myriam ^a   Chariot, Patrick ^a,b  

^a HENRI MONDOR HOSPITAL   (France)

^b UNIVERSITÉ PARIS EST CRÉTEIL   (France)

Author keywords

Cyclosporine A; Mitochondria; Myopathy; Skeletal muscle; Systematic review; Toxicity

Indexed keywords

AMITRIPTYLINE; CLONAZEPAM; COLCHICINE; CREATINE KINASE; CYCLOSPORIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PYRAZINAMIDE; STATIN;

AGED; CASE REPORT; DATA BASE; DISEASE ASSOCIATION; ENDURANCE; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; MUSCLE BIOPSY; MUSCLE DISEASE; MUSCLE MITOCHONDRION; MUSCLE STRENGTH; MUSCLE WEAKNESS; MUSCULAR DYSTROPHY; MYALGIA; MYOPATHY; NEPHROTOXICITY; PRIORITY JOURNAL; REVIEW; SKELETAL MUSCLE;

ANIMALS; CYCLOSPORINE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MUSCLE, SKELETAL; MUSCULAR DISEASES;

EID: 0032709858     PISSN: 0148639X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-4598(199912)22:12<1631::AID-MUS3>3.0.CO;2-V     Document Type: Review

References (60)

1. Alejandro DSJ, Petersen J. Myoglobinuric acute renal failure in a cardiac transplant patient taking lovastatin and cyclosporine. J Am Soc Nephrol 1994;5:153-160.
2. Arellano F, Krupp P. Muscular disorders associated with cyclosporin. Lancet 1991;337:915.
3. Arnadottir M, Eriksson LO, Thysell H, Karkas JD. Plasma concentration profiles of symvastatin 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin. Nephron 1993;65: 410-413.
4. Atkison P, Joubert G, Barron A, Grant D, Paradis K, Seidman E, Wall W, Rosenberg H, Howard J, Williams S, Stiller C. Hypertrophic cardiomyopathy associated with tacrolimus in paediatric transplant patients. Lancet 1995;345:894-896.
5. Bennett WM, Norman DJ. Action and toxicity of cyclosporin. Ann Rev Med 1986;37:215-224.
6. Bernardi P, Broekemeier KM, Pfeiffer DR. Recent progress on regulation of the mitochondrial permeability transition pore; a cyclosporin-sensitive pore in the inner mitochondrial membrane. J Bioenerg Biomembr 1994;26:509-517.
7. Biring MS, Fournier M, Ross DJ, Lewis MI. Cellular adaptations of skeletal muscles to cyclosporine. J Appl Physiol 1998; 84:1967-1975.
8. Blaison G, Weber JC, Sachs D, Korganow AS, Martin T, Kretz JG, Pasquali JL. Rhabdomyolyse causée par la simvastatine chez un transplanté cardiaque sous ciclosporine. Rev Med Interne 1992;13:61-63.
9. Borel JF, Kis ZL. The discovery and development of cyclosporine. Transplant Proc 1991;23:1867-1874.
10. Budak-Alpdogan T, Kalayoglu-Besisik S, Sargin D, Tangun Y. Cyclosporin related reversible muscular toxicity. Bone Marrow Transplant 1998;22:115-116.
11. Chagnac A, Wisnovitz M, Zevin D, Korzets A, Mittelman M, Levi J. Cyclosporin-associated rhabdomyolysis and anterior compartment syndrome in a renal transplant recipient. Clin Nephrol 1993;39:351-352.
12. Corpier CL, Jones PH, Suki WN, Lederer ED, Quinones MA, Schmidt SW, Young JB. Rhabdomyolysis and renal injury with lovastatin use. Report of two cases in cardiac transplant recipients. JAMA 1988;260:239-241.
13. Costigan DA. Acquired myotonia, weakness and vacuolar myopathy secondary to cyclosporine. Muscle Nerve 1989;12:761 (abstract).
14. Crompton M, McGuinness O, Nazareth W. The involvement of cyclosporin A binding proteins in regulating and uncoupling mitochondrial energy transduction. Biochim Biophys Acta 1992;1101:214-217.
15. Ducloux D, Schuller V, Bresson-Vautrin C, Chalopin JM. Colchicine myopathy in renal transplant recipients on cyclosporin. Nephrol Dial Transplant 1997;12:2389-2392.
16. East C, Alivizatos PA, Grundy SM, Jones PH, Farmer JA. Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation. N Engl J Med 1988;318:47-48.
17. Fernandez-Sola J, Campistol JM, Casademont J, Grau JM, Urbano-Marquez A. Reversible cyclosporin myopathy. Lancet 1990;335:362-363.
18. Fernandez-Sola J, Campistol JM, Miro O, Garces N, Soy D, Grau JM. Acute toxic myopathy due to pyrazinamide in a patient with renal transplantation and cyclosporin therapy. Nephrol Dial Transplant 1996;11:1850-1852.
19. Fournier N, Ducet G, Crevat A. Action of cyclosporine on mitochondrial calcium fluxes. J Bioenerg Biomembr 1987;19: 297-303.
20. Goy JJ, Stauffer JC, Deruaz JP, Gillard D, Kaufmann U, Kuntzer T, Kappenberger L. Myopathy as possible side-effect of cyclosporin. Lancet 1989;1:1446-1447.
21. Grezard O, Lebranchu Y, Birmele B, Sharobeem R, Nivet H, Bagros P. Cyclosporin-induced muscular toxicity. Lancet 1989;335:177.
22. Heffner RR, Barron SA. The early effects of ischemia upon skeletal muscle mitochondria. J Neurol Sci 1978;38:295-315.
23. Henke W, Klotzek S, Nickel E, Dippe M, Jung K. Ischemia-induced alterations of rat kidney mitochondria. Transplantation 1990;49:997-999.
24. Henke W, Nickel E, Jung K. Cyclosporine A inhibits ATP net uptake of rat kidney mitochondria. Biochem Pharmacol 1992; 43:1021-1024.
25. Hibi S, Misawa A, Tamai M, Tsunamoto K, Todo S, Sawada T, Imashuku S. Severe rhabdomyolysis associated with tacrolimus. Lancet 1995;346:702.
26. Hokanson JF, Mercier JG, Brooks GA. Cyclosporine A decreases rat skeletal muscle mitochondrial respiration in vitro. Am J Respir Crit Care Med 1995;151:1848-1851.
27. Jackson NM, O'Connor RP, Humes HD. Interactions of cyclosporine with renal proximal tubule cells and cellular membranes. Transplantation 1988;46:109-114.
28. Jagose JT, Bailey RR. Muscle weakness due to colchicine in a renal transplant recipient. NZ Med J 1997;110:343.
29. Jung K, Pergande M. Influence of cyclosporin A on the respiration of isolated rat kidney mitochondria. FEBS Lett 1985; 183:167-169.
30. Jung K, Reinhodt C, Scholz D. Inhibitory effect of cyclosporine on the respiratory efficiency of isolated human kidney mitochondria. Transplantation 1987;43:162-163.
31. Kavanagh T, Yacoub MH, Mertens DJ, Kennedy J, Campbell RB, Sawyer P. Cardiorespiratory responses to exercise training after orthotopic cardiac transplantation. Circulation 1988;77: 162-171.
32. Klintmalm GB, Iwatsuki S, Starzl TE. Cyclosporin A hepatotoxicity in 66 renal allograft recipients. Transplantation 1981; 32:488-489.
33. Kobashigawa JA, Murphy FL, Stevenson LW, Moriguchi JD, Kawata N, Kamjoo P, Brownfield E, Wilmarth J, Leonard L, Chuck C, Drinkwater D, Laks H. Low-dose lovastatin safely lowers cholesterol after cardiac transplantation. Circulation 1990;82(Suppl IV):281-283.
34. Lampert E, Mettauer B, Hoppeler H, Charloux A, Charpentier A, Lonsdorfer J. Stucture of skeletal muscle in heart transplant recipients. J Am Coll Cardiol 1996;28:980-984.
35. Lamer AJ, Sturman SG, Hawkins JB, Anderson M. Myopathy with ragged red fibres following renal transplantation: possible role of cyclosporin-induced hypomagnesaemia. Acta Neuropathol 1994;88:189-192.
36. Lee BI, Shin SJ, Yoon SN, Choi YJ, Yang CW, Bang BK. Acute myopathy induced by colchicine in a cyclosporine-treated renal transplant recipient. J Korean Med Sci 1997;12:160-161.
37. Lemmi CAE, Pelikan PCD, Sikka SC, Hirschberg R, Geesaman B, Miller RL, Park KS, Liu SC, Koyle M, Rajfer J. Cyclosporine augments renal mitochondrial function in vivo and reduces renal blood flow. Am J Physiol 1989;257:F837-F841.
38. Lucas VP, Ponge TD, Plougastel-Lucas ML, Glemain P, Hourmant M, Soulillou JP. Musculoskeletal pain in renal transplant recipients. N Engl J Med 1991;325:1449.
39. Mendell JR, Kissel JT, Amato AA, King W, Signore L, Prior TW, Sahenk Z, Benson S, McAndrew PE, Rice R, Nagaraja H, Stephens R, Lantry L, Morris GE, Burghes AHM. Myoblast transfer in the treatment of Duchenne's muscular dystrophy. N Engl J Med 1995;333:832-838.
40. Mercier JG, Hokanson JF, Brooks GA. Effects of cyclosporine A on skeletal muscle mitochondrial respiration and endurance time in rats. Am J Respir Crit Care Med 1995;151: 1532-1536.
41. Miller RG, Sharma KR, Pavlath GK, Gussoni E, Mynhier M, Yu P, Lanctot AM, Greco CM, Steinman L, Blau HM. Myoblast implantation in Duchenne muscular dystrophy: the San Francisco study. Muscle Nerve 1997;20:469-478.
42. Mittnacht S, Sherman SC, Farber JL. Reversal of ischemic mitochondrial dysfunction. J Biol Chem 1979;254:9871-9878.
43. Nicolli A, Basso E, Petronilli V, Wenger RM, Bernardi P. Interactions of cyclophilin with the mitochondrial inner membrane and regulation of the permeability transition pore, a cyclosporin A-sensitive channel. J Biol Chem 1996;271: 2185-2192.
44. Noppen M, Velkeniers B, Dierckx R, Bruyland M, Vanhaelst L. Cyclosporin and myopathy. Ann Intern Med 1987;107: 945-946.
45. Norman DJ, Illingworth DR, Munson J, Hosenpud J. Myolysis and acute renal failure in heart-transplant recipient receiving lovastatin. N Engl J Med 1988;318:46-47.
46. Rana SS, Giuliani MJ, Oddis CV, Lacomis D. Acute onset of colchicine myoneuropathy in cardiac transplant recipients: case studies of three patients. Clin Neurol Neurosurg 1997; 99:266-270.
47. Rieger EH, Halasz NA, Wahlstrom HE. Colchicine neuromyopathy after renal transplantation. Transplantation 1990;49: 1196-1198.
48. Rush DN. Cyclosporine toxicity to organs other than the kidney. Clin Biochem 1991;24:101-105.
49. Ryffel B, Donatsch P, Madorin M, Matter BE, Ruttimann G, Schon H, Stoll R, Wilson J. Toxicological evaluation of cyclosporin A. Arch Toxicol 1983;53:107-141.
50. Schlegel J, Meier P, Kass GEN, Richter C. Inhibition by cyclosporin A of the prooxidant-induced calcium release from rat kidney mitochondria. Biochem Pharmacol 1991;42: 2193-2197.
51. Schmid H, Schmitt H, Eissele R, Neuhaus G. Nephrotoxicity of cyclosporine A in the rat. Renal Physiol Biochem 1993;16: 146-155.
52. Segaert MF, De Soete C, Vandewiele I, Verbanck J. Drug-interaction-induced rhabdomyolysis. Nephrol Dial Transplant 1996;11:1846-1847.
53. Sharma KR, Mynhier MA, Miller RG. Cyclosporine increases muscular force generation in Duchenne muscular dystrophy. Neurology 1993;43:527-532.
54. Simon N, Zini R, Morin C, Bree F, Tillement JP. Prednisolone and azathioprine worsen the cyclosporin A-induced oxidative phosphorylation decrease of kidney mitochondria. Life Sci 1997;61:659-666.
55. Smith PF, Eydelloth RS, Grossman SJ, Stubbs RJ, Schwartz MS, Germershausen JI, Vyas KP, Kari PH, MacDonald JS. HMG-CoA reductase inhibitor-induced myopathy in the rat: cyclosporin A interaction and mechanism studies. J Pharmacol Exp Ther 1991;257:1225-1235.
56. Smith PF, Eydelloth RS, Grossman SJ, Stubbs RJ, Schwartz MS, Germershausen JI, MacDonald JS. Myopathy associated with HMGCoA reductase inhibitors and cyclosporin A: evaluation in a rat model. Eur Heart J 1992;13(Suppl B):2-6.
57. Stratton JR, Kemp GJ, Daly RC, Yacoub M, Rajagopalan B. Effects of cardiac transplantation on bioenergetic abnormalities of skeletal muscle in congestive heart failure. Circulation 1994;89:1624-1631.
58. Strzelecki T, Kumar S, Khauli R, Menon M. Impairment by cyclosporine of membrane-mediated functions in kidney mitochondria. Kidney Int 1988;34:234-240.
59. Yussim A, Bar-Nathan N, Lustig S, Shaharabani E, Geier E, Shmuely D, Nakache R, Shapira Z. Gastrointestinal, hepatorenal, and neuromuscular toxicity caused by cyclosporine-colchicine interaction in renal transplantation. Transplant Proc 1994;26:2825-2826.
60. Zoratti M, Szabo I. The mitochondrial permeability transition. Biochim Biophys Acta 1995;1241:139-176.